U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb ’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE) February 13, 2020 --Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news

Related Links:

CONCLUSION: This case report demonstrates a possible severe adverse effect of the immunomodulatory drug ibrutinib and the importance of a multidisciplinary approach in its diagnosis. Since PML is a rare but highly fatal disease, it is of utmost importance to be aware of the possible connection with the use of this drug to prevent missed or delayed diagnosis, considering that timely therapeutic intervention is crucial for improved prognosis.
. PMID: 32213285 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research
Abstract Gastrointestinal (GI) diffuse large B-cell lymphoma (DLBCL) is one of the frequently reported histologic subtypes of non-Hodgkin lymphoma (NHL) that occur in the GI tract. However, the presentation of quite different clinical manifestations, morphologic characteristics, immunophenotypes, and molecular biologic features is challenging for its diagnosis. Herein, we describe a rare case of primary colorectal DLBCL that occurred in a 59-year-old immunocompetent Chinese female who attended our respiratory clinic for the third time with an asymptomatic pleural effusion and pleural thickening. In her clinical se...
Source: International Journal of Clinical and Experimental Pathology - Category: Pathology Authors: Tags: Int J Clin Exp Pathol Source Type: research
CONCLUSION: This preliminary investigation in Iran shows that the main EBV genotype into our region probably is genotype I (91.2%) which it is similar to others. We could not find any statistically significant association between the virus infection and viral load with any specific disease and patients' demographic data. . PMID: 32212795 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Authors: Choi Y, Yoo JH, Lee JH, Lee Y, Bae MK, Kim YD, Kim HJ Abstract Connective tissue growth factor (CTGF), an extracellular matrix protein with various biological functions, is known to be upregulated in multiple chronic diseases such as liver fibrosis and congestive heart failure, but the mechanism it undertakes to cause alveolar bone loss in periodontitis remains elusive. The present study therefore investigates the pathways involving CTGF in chronic periodontitis. RNA sequencing revealed a notable increase in the expression of CTGF in chronic periodontitis tissues. Also, TRAP staining, TRAP activity and bon...
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
AbstractBackgroundSALL4 is a zinc finger transcription factor that exerts its physiological role during embryo-fetal development. Analyses of SALL4 expression have shown its oncogenic role in precursor B-cell lymphoblastic lymphoma, acute and chronic myeloid leukemia, gastrointestinal, breast, and lung cancers. The aim of this study was to determine the immunohistochemical profile of SALL4 in pediatric yolk sac tumors (YSTs).Methods and resultsImmunohistochemistry detection of SALL4 was performed in 22 cases of pediatric YSTs and 10 mature teratomas. The percentage of tumor cells stained was scored as 0, 1+  (1&ndas...
Source: Pediatric Surgery International - Category: Surgery Source Type: research
ConclusionsPola PK was well characterized with no clinically meaningful DDIs with R/G-CHP. Findings are consistent with previous studies of pola  + R/G, and support pola + R/G-CHP use in previously untreated diffuse large B-cell lymphoma.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Condition:   Relapsed / Refractory Follicular Lymphoma Intervention:   Drug: TQ-B3525 Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Ann Arbor Stage II Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage II Follicular Lymphoma;   Ann Arbor Stage II Marginal Zone Lymphoma;   Ann Arbor Stage III Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage III Follicular Lymphoma;   Ann Arbor Stage III Ma rginal Zone Lymphoma;   Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage&n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: In patients with early-stage nasal NKTCL, our LVD-IMRT regimen produced excellent, durable therapeutic benefit in most patients, with acceptable toxicity and no acute mortality.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Head and Neck Source Type: research
More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Lymphoma | New Drug Applications